Print Page      Close Window

2017 Press Releases


Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle 
12/14/17Tocagen Added to NASDAQ Biotechnology Index
SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI), which will become effective prior to the open of U.S. markets on Monday, December 18, 2017. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classifie... 
Printer Friendly Version
11/21/17Tocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive Conference
SAN DIEGO, Nov. 21, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a change to the company's presentation time at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston. Marty Duvall, chief executive officer, will now present at 1:35 p.m. ET on Wednesday, November 29. The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen's website. The we... 
Printer Friendly Version
11/10/17Tocagen to Present at Two Investor Conferences in November
SAN DIEGO, Nov. 10, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Marty Duvall, chief executive officer, will present at the following upcoming investor conferences: Stifel Nicolaus Healthcare Conference, Tuesday, November 14, 11:45 a.m. ET in New York City Evercore ISI Biopharma Catalyst/Deep Dive Conference, Wednesday, November 29, 2:00 p.m. ET in Boston The liv... 
Printer Friendly Version
11/09/17Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific Conferences
SAN DIEGO, Nov. 9, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced seven presentations of updated clinical and preclinical data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting & Pre-Conference Programs, held Nov. 8-12 in National Harbor, Maryland, the 2017 Society for Neuro-Oncology (SNO) and the Society for CNS Interstitial Delivery of Therapeutics (SCIDOT) Joint Conference on Therapeutic Delive... 
Printer Friendly Version
11/08/17Tocagen Reports Third Quarter 2017 Financial and Business Results
SAN DIEGO, Nov. 8, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the third quarter ended September 30, 2017 and business highlights. "Recent operational highlights include the acceleration of Toca 511 & Toca FC development into a pivotal Phase 3 trial and the presentation of updated Phase 1 data in patients with recurrent high-grade glioma at the recent AACR-... 
Printer Friendly Version
11/01/17Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8
SAN DIEGO, Nov. 1, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its third quarter 2017 financial results and business progress on Wednesday, November 8, 2017, after the close of the U.S. financial markets. To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts.... 
Printer Friendly Version
10/27/17Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade Glioma
All responders now in complete response; median duration of response not reached after nearly 3 years of follow up SAN DIEGO, Oct. 27, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported updated data demonstrating long-term durable responses, and the conversion of initial partial responses (PRs) into complete responses (CRs), from a Phase 1 study of Tocagen's investigational product, Toca 511 & Toca FC, for the treatmen... 
Printer Friendly Version
10/26/17Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 Trial
SAN DIEGO, Oct. 26, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the company has updated the protocol of the ongoing Toca 5 clinical trial of Toca 511 & Toca FC for the treatment of patients with recurrent high-grade glioma (HGG), a type of brain tumor. Based on Tocagen's communications with the U.S. Food and Drug Administration (FDA) under Breakthrough Therapy Designation, Toc... 
Printer Friendly Version
10/17/17Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data selected for inclusion in official press program of AACR-NCI-EORTC on October 27, 2017 SAN DIEGO, Oct. 17, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that updated data from the company's Phase 1 study of Toca 511 & Toca FC in recurrent high grade glioma (brain cancer), have been selected for an oral presentation at the annual International Conference on Molecular Targets and Cancer Therapeutics of the Ame... 
Printer Friendly Version
08/09/17Tocagen Reports Second Quarter 2017 Financial and Business Results
SAN DIEGO, Aug. 9, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the second quarter ended June 30, 2017 and business highlights. "Tocagen is committed to bringing new treatment options to cancer patients, with an initial focus on recurrent high grade glioma," said Marty Duvall, chief executive officer of Tocagen. "During the second quarter, we completed our initi... 
Printer Friendly Version
08/02/17Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9
SAN DIEGO, Aug. 2, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its second quarter 2017 financial results and business progress on Wednesday, August 9, 2017, after the close of the U.S. financial markets. To receive Tocagen's press releases and other investor information, please visit the Investor Relations page of the company's website and register for email alerts. ... 
Printer Friendly Version
07/24/17Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma
SAN DIEGO, July 24, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the European Medicines Agency (EMA) has granted Toca 511 (vocimagene amiretrorepvec) PRIME (PRIority MEdicines) designation for the treatment of patients with high grade glioma (HGG), a type of brain tumor. Toca 511 & Toca FC is currently under evaluation in an international, randomized Phase 2/3 clinical trial, which is designed to serve as a potenti... 
Printer Friendly Version
06/19/17Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FC
Increased immune infiltrates in tumor demonstrated Long-term survival and anti-tumor immune effects shown to be T cell-dependent and correlate with depletion of immune-suppressive myeloid cells SAN DIEGO, June 19, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the publication of preclinical data in Neuro-Oncology from two independent research programs which together detail proposed mechanisms of action for Toca 511... 
Printer Friendly Version
05/23/17Tocagen Reports First Quarter 2017 Financial and Business Results
Upsized initial public offering completed, raising approximately $97.8 million in gross proceeds SAN DIEGO, May 23, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results for the first quarter ended March 31, 2017 and business highlights. "Tocagen has made great strides in our mission to bring novel and effective cancer-selective immunotherapies to patients, with an initial focus on brain cancer. Key mile... 
Printer Friendly Version
05/11/17Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting
SAN DIEGO, May 11, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it presented data at the American Society of Gene and Cell Therapy 20th Annual Meeting (ASGCT). Details of the presentations are as follows. The presentation slides and poster can be accessed by visiting the publications and presentations section of the Company's website at www.tocagen.com. Title: Long-term follow-u... 
Printer Friendly Version
04/19/17Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option
SAN DIEGO, April 19, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the closing of its initial public offering of common stock, including the underwriters' exercise of their option to purchase an additional 1,275,000 shares at the public offering price of $10.00 per share. The underwriters' option brought the total number of shares of common stock sold by Tocagen to 9,775,000 shares and increased the amount of gross proc... 
Printer Friendly Version
04/13/17Tocagen Announces Pricing of Initial Public Offering
SAN DIEGO, April 13, 2017 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a public offering price of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Select Market on April 13, 2017 under the ticker symbol "TOCA." In addition, Tocagen has granted the underwriters a 30-day option to purchase up to an additional 1,275... 
Printer Friendly Version
03/16/17Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia
SAN DIEGO – March 16, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced preclinical and clinical data will be presented at the 2017 Keystone Symposia on Molecular and Cellular Biology: Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology (C7), to be held March 19-23 in Whistler, British Columbia.Details of the poster presentation are as follows:Title: Preclinical and Clinical Data Support Anti-tumor Cellular Immune Response Elicit... 
Printer Friendly Version
03/07/17Tocagen Appoints Mark Foletta as Executive Vice President and Chief Financial Officer
SAN DIEGO – March 7, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the appointment of Mark Foletta as executive vice president and chief financial officer, succeeding Tom Darcy, a company co-founder who is retiring. Mr. Darcy will continue to serve on the company's board of directors."Mark is a proven leader with deep experience building successful biopharmaceutical companies," said Marty Duvall, Tocagen's chief executive officer. "With the recent ... 
Printer Friendly Version
02/23/17Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled Top-Line Results Anticipated 1H 2018
SAN DIEGO – Feb. 23, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced it has completed patient enrollment in the Phase 2 portion of Toca 5, a randomized, international Phase 2/3 clinical trial of Toca 511 & Toca FC, for the treatment of patients with recurrent brain cancer.Toca 5 is designed to serve as a potential registrational trial, and top-line results from the Phase 2 portion are anticipated in the first half of 2018. In the trial, patients with... 
Printer Friendly Version
02/23/17Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade Glioma
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Toca 511 & Toca FC Breakthrough Therapy Designation for the treatment of patients with recurrent high grade glioma (HGG). Toca 511 & Toca FC is currently under evaluation in an international, randomized Phase 2/3 clinical trial, which is designed to serve as a potential registrational study. The trial involves patients with first or second re... 
Printer Friendly Version
01/17/17Tocagen to Present at Phacilitate Cell & Gene Therapy World 2017
SAN DIEGO – Jan. 17, 2017 – Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced Douglas J. Jolly, Ph.D., executive vice president, research and pharmaceutical development at Tocagen, will present at Phacilitate Cell & Gene Therapy World 2017, to be held Jan. 17-20 in Miami.Details of the podium presentation are as follows:Dr. Jolly's podium presentation will focus on gene therapy manufacturing and will be delivered on Wednesday, Jan. 18, 1:05-1:25 p.m. ET.About... 
Printer Friendly Version
01/13/17Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea
SAN DIEGO – Jan. 13, 2017 — Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, today announced its randomized, controlled Phase 2/3 clinical trial, called Toca 5, is now enrolling patients in South Korea. The trial is ongoing in the United States, Canada and Israel. The study compares a cancer-selective virus, Toca 511 (vocimagene amiretrorepvec), in combination with Toca FC (extended-release 5-fluorocytosine), to standard of care in patients with first or second recurre... 
Printer Friendly Version